Expertise in
25
conditions

Dr. Anuradha Belur

Hematology | Oncology
Multicare Cancer Institute-Auburn
121 N Division St Ste 100, 
Auburn, WA 
Offers Telehealth
Expertise in
25
conditions
Multicare Cancer Institute-Auburn
121 N Division St Ste 100, 
Auburn, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anuradha Belur is a Hematologist and an Oncologist in Auburn, Washington. Dr. Belur is highly rated in 25 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Multiple Myeloma.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Multicare Auburn Medical Center
Tacoma General Allenmore Hospital
Multicare Covington Medical Center
Multicare Good Samaritan Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Multicare Cancer Institute-Auburn
121 N Division St Ste 100, Auburn, WA 98001

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Drug
Study Drug: Crofelemer [Mytesi]
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

1 Total Publications

Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.
Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.
Journal: Case reports in medicine
Published: May 19, 2018
Similar Doctors
Expertise in
17
conditions
Dr. Hans-peter Kiem
Hematology | Oncology
Expertise in
17
conditions
Dr. Hans-peter Kiem
Hematology | Oncology

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (23.8 miles away)
206-543-3360
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans-peter Kiem is a Hematologist and an Oncologist in Seattle, Washington. Dr. Kiem is highly rated in 17 conditions, according to our data. His top areas of expertise are X-Linked Severe Combined Immunodeficiency, Congenital Aplastic Anemia, Fanconi Anemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant.

Expertise in
16
conditions
Dr. Douglas Hawkins
Hematology | Oncology
Expertise in
16
conditions
Dr. Douglas Hawkins
Hematology | Oncology

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (24.5 miles away)
206-987-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist in Seattle, Washington. Dr. Hawkins is highly rated in 16 conditions, according to our data. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration.

Expertise in
7
conditions
Dr. Mignon Loh
Hematology | Oncology
Expertise in
7
conditions
Dr. Mignon Loh
Hematology | Oncology

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (24.5 miles away)
206-987-2106
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mignon Loh is a Hematologist and an Oncologist in Seattle, Washington. Dr. Loh is highly rated in 7 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Juvenile Myelomonocytic Leukemia (JMML), Leukemia, Splenectomy, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Belur's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 84 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile